

AUSTRALIAN PRODUCT INFORMATION - NOUMED AZATHIOPRINE

1. NAME OF THE MEDICINE

Azathioprine

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NOUMED AZATHIOPRINE film-coated tablets contain 25 mg or 50 mg of azathioprine.

Excipients with known effect: sugars (as lactose). For the full list of excipients, see **section 6.1 List of excipients**.

3. PHARMACEUTICAL FORM

NOUMED AZATHIOPRINE tablets are round, biconvex, white to yellowish-white, film-coated tablets with no marks or embossments. The 50 mg tablet has a one-sided breaking notch.

4. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.

Azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants.

Azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

4.2 DOSE AND METHOD OF ADMINISTRATION

Specialist medical literature should be consulted for guidance as to clinical experience in particular conditions.

Dosage in transplantation

Adults and children: Depending on the immunosuppressive regimen adopted, a loading dose of up to 5 mg/kg/day is usually given.

Maintenance dosage may range from 1 to 4 mg/kg/day and must be adjusted according to clinical requirements and haematological tolerance.

Evidence indicates that azathioprine therapy should be maintained indefinitely, even if only low doses are necessary, because of risk of graft rejection.

Dosage in other conditions

Adults and children: In general, the initial dose should be approximately 1.0 mg/kg/day (50 to 100 mg) gradually increasing in increments of 0.5 mg/kg/day over several weeks, if necessary up to a maximum dose of 2.5 mg/kg/day.

When therapeutic response is evident, consideration should be given to reducing the maintenance dosage to the lowest level compatible with maintenance of that response. If no improvement occurs in the patient's condition within three months, consideration should be given to withdrawing azathioprine.

The maintenance dosage required may range from less than 1 mg/kg/day, to 3 mg/kg/day, depending on the clinical condition being treated and the individual patient response, including haematological tolerance.

Use in the elderly

See **section 4.4 Special warnings and precautions for use – Use in renal and/or hepatic impairment.**

The rapid *in vivo* cleavage of the azathioprine molecule followed by tissue fixation makes it impossible to relate plasma drug levels to toxicity. There are no specific data as to the tolerance of azathioprine in elderly patients. It is recommended that the dosages used are at the lower end of the range given for adults and children.

Particular care should be taken to monitor haematological response and to reduce the maintenance dosage to the minimum required for clinical response.

Method of administration

Azathioprine tablets should be administered at least 1 hour before or 3 hours after food or milk.

4.3 CONTRAINDICATIONS

Hypersensitivity to azathioprine or to any of the ingredients of this product (see **section 6.1 List of excipients**). Hypersensitivity to 6-mercaptopurine (6-MP) should alert the prescriber to probable hypersensitivity to azathioprine.

Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan or others) may have a prohibitive risk of neoplasia if treated with azathioprine.

Azathioprine therapy should not be initiated in patients who may be pregnant, who are likely to become pregnant in the near future, or who are known to be pregnant (see **section 4.4 Special warnings and precautions for use**).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Co-administration of ribavirin and azathioprine is not advised. Ribavirin may reduce efficacy and increase toxicity of azathioprine.

Monitoring

There are potential hazards to the use of azathioprine. It should be prescribed only if the patient can be adequately monitored for toxic effects throughout the duration of therapy.

Particular care should be taken to monitor haematological response and to reduce the maintenance dosage to the minimum required clinical response.

During the first eight weeks of therapy, complete blood counts, including platelets, must be performed weekly or more frequently if high dosage is used or if severe renal and/or hepatic disorder is present. The blood count frequency may be reduced later in therapy, but it is recommended that complete blood counts are repeated at intervals of not longer than one month or more frequently if dosage alterations or other changes to therapy are made. Delayed haematological suppression may occur.

Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in, or persistently low, leucocyte count or other evidence of bone marrow depression.

Patients receiving azathioprine should be instructed to report immediately if there is any evidence of infection, unexpected bruising or bleeding, black tarry stools and blood in the urine or stools, or other manifestations of bone marrow depression. Bone marrow suppression is reversible if azathioprine is withdrawn early enough.

Azathioprine is hepatotoxic and liver function tests should be routinely monitored during treatment. More frequent monitoring may be advisable in those with pre-existing liver disease or receiving other potentially hepatotoxic therapy.

The patient should be instructed to discontinue azathioprine immediately if jaundice becomes apparent.

TPMT testing

There are individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of azathioprine and prone to developing rapid bone marrow depression following the initiation of treatment with azathioprine. There have been fatal cases of myelosuppression in patients with low or absent TPMT activity treated with thiopurines. This problem could be exacerbated by co-administration with drugs that inhibit TPMT, such as olsalazine, mesalazine or sulfasalazine. Also a possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6-mercaptopurine (the active metabolite of azathioprine) in combination with other cytotoxics [see **section 4.8 Adverse effects (Undesirable effects)**].

TPMT testing is widely available through pathology laboratories and genetic testing services. Patients should be tested for TPMT activity before starting azathioprine. TPMT testing cannot substitute for complete blood count monitoring in patients receiving azathioprine. TPMT genotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity (homozygous for non-functional alleles) are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine if conventional doses are given. Alternative therapies may be considered for patients who have low or absent TPMT activity. Azathioprine should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. The dosage of azathioprine may need to be reduced when this agent is combined with other drugs whose primary or secondary toxicity is myelosuppression.

NUDT15 testing

Patients with inherited mutated NUDT15 gene are at increased risk for severe thiopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy and generally require substantial dose reduction. The precise mechanism of NUDT 15-associated thiopurine-related toxicity is not understood. Patients of Asian ethnicity are particularly at risk, due to the increased frequency of the mutation in this population. The optimal starting dose for heterozygous or homozygous deficient patients has not been established. Close monitoring of blood count is necessary.

Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including paediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations.

Use in renal and/or hepatic impairment

It is impossible to relate plasma levels of azathioprine or 6-mercaptopurine to therapeutic efficacy or toxicity. Conversion of 6-thioinosinic acid to 6-thiouric acid by xanthine oxidase is not dependent on intact hepatic and/or renal function. Nevertheless, it is recommended that the dosages used are at the lower end of the normal range and that haematological response is carefully monitored. Dosage should be further reduced if haematological toxicity occurs.

Caution is necessary during the administration of azathioprine to patients with hepatic dysfunction, and regular complete blood counts and liver function tests should be undertaken. In such patients the metabolism of azathioprine may be impaired, and the dosage of azathioprine should therefore be reduced to the lower end of the recommended range. Dosage should be further reduced if hepatic or haematological toxicity occurs.

Lesch-Nyhan syndrome

Limited evidence suggests that azathioprine is not beneficial to patients with hypoxanthine-guanine-phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome). Therefore, given the abnormal metabolism in these patients, it is not prudent to recommend that these patients should receive azathioprine.

Varicella Zoster Virus Infection

Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts (see **section 4.8 Adverse effects (Undesirable effects)**). Therefore, immunisations with live organism vaccines are not recommended.

Infection with varicella zoster virus (VZV; chicken pox and herpes zoster) may become severe during the administration of immunosuppressants. Caution should be exercised especially with respect to the following:

- before starting the administration of the immunosuppressants, the prescriber should check to see if the patient has a history of VZV. Serologic testing may be useful in determining previous exposure. Patients who have no history of exposure should avoid contact with individuals with chickenpox or herpes zoster. If the patient is exposed to VZV, special care must be taken to avoid patients developing chicken pox or herpes zoster, and passive immunisation with varicella-zoster immunoglobulin (VZIG) may be considered.
- if the patient is infected with VZV, appropriate measures should be taken, which may include antiviral therapy and supportive care.

Cytomegalovirus (CMV) disease

Cytomegalovirus (CMV) viraemia resulting in serious pneumonitis and associated haemophagocytic syndrome manifesting in patients with inflammatory bowel disease (IBD) has been reported in the literature [see **section 4.8 Adverse effects (Undesirable effects)**].

Caution should be exercised and specialist literature consulted when determining the risks of CMV reactivation and IBD deterioration.

Progressive Multifocal Leukoencephalopathy (PML)

PML, an opportunistic infection caused by the JC virus (a type of human polyomavirus) has been reported in patients receiving azathioprine with other immunosuppressive agents. Immunosuppressive therapy should be withheld at the first sign or symptoms suggestive of PML and appropriate evaluation undertaken to establish a diagnosis [see **section 4.8 Adverse effects (Undesirable effects)**].

Hepatitis B

Hepatitis B carriers (defined as patients positive for hepatitis B surface antigen [HBsAg] for more than six months), or patients with documented past HBV infection, who receive immunosuppressive drugs are at risk of reactivation of HBV replication, with asymptomatic increases in serum HBV DNA and ALT levels [see **section 4.8 Adverse effects (Undesirable effects)**]. Specialist medical literature should be consulted for guidance including prophylactic therapy with oral anti-HBV agents.

Macrophage activation syndrome

Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD), and there could potentially be an increased susceptibility for developing the condition with the use of azathioprine. If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with azathioprine should be discontinued. Doctors should be attentive to symptoms of infection such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), as these are known triggers for MAS.

Mutagenicity

Chromosomal abnormalities, which can occur independently of the influence of azathioprine, have been demonstrated in both male and female transplant recipients.

Chromosomal abnormalities which disappear in time have been demonstrated in offspring of transplant recipients. Except in extremely rare cases, no overt physical evidence of abnormality has been observed in these offspring.

Azathioprine and long-wave ultraviolet light have been shown to have a synergistic clastogenic effect in patients treated with azathioprine for a range of disorders.

Carcinogenicity

Patients receiving immunosuppressive therapy, including azathioprine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer *in situ* [see **section 4.8 Adverse effects (Undesirable effects) - Neoplasms benign and malignant (including cysts and polyps)**]. The increased risk appears to be related to the degree and duration of immunosuppression rather than to the use of any specific agent. It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.

Patients receiving multiple immunosuppressive (including thiopurines) agents may be at risk of over-immunosuppression that could lead to lymphoproliferative disorders, some with reported fatalities, therefore such therapy should be maintained at the lowest effective level. A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.

As is usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited, and patients should wear protective clothing and use a sunscreen with a high protection factor.

Renal transplant recipients in some geographical areas are at greater risk of skin cancers than those in other areas.

Other neoplasms reportedly associated with azathioprine include carcinoma of the urinary bladder and adenocarcinoma of the lung.

Hypersensitivity

Patients suspected to have previously presented a hypersensitivity reaction to 6-mercaptopurine should not be recommended to use its pro-drug azathioprine, and vice-versa, unless the patient has been confirmed as hypersensitive to the culprit drug with allergological tests, and tested negative for the other. See also **section 4.3 Contraindications**.

Other precautions

Azathioprine should be used with caution in hypersplenism.

Withdrawal of azathioprine should be gradual and performed under close supervision.

Dental work, whenever possible, should be completed prior to initiation of azathioprine therapy or deferred until blood counts are normal.

Use in the elderly

See **sections 4.2 Dose and method of administration - Use in the elderly** and **4.4 Special warnings and precautions for use - Use in renal and/or hepatic impairment**.

Paediatric use

No data available.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Allopurinol and other xanthine oxidase inhibitors

Xanthine oxidase activity is inhibited by allopurinol, oxipurinol and thiopurinol which results in reduced conversion of biologically active 6-thioinosinic acid to biologically inactive 6-thiouric acid. When allopurinol, oxipurinol and/or thiopurinol are given concomitantly with 6-mercaptopurine (6-MP) or azathioprine, the dose of 6-MP and azathioprine should be reduced to one-quarter of the original dose.

Other xanthine oxidase inhibitors, such as febuxostat may decrease the metabolism of azathioprine. Concomitant administration is not recommended as data are insufficient to determine an adequate dose reduction.

Neuromuscular blocking agents

Azathioprine can potentiate the neuromuscular blockade produced by depolarising agents such as succinylcholine (suxamethonium) and reduce the blockade produced by non-depolarising agents such as tubocurarine.

Anticoagulants

Inhibition of the anticoagulant effect of warfarin and acenocoumarol has been reported when co-administered with azathioprine. Therefore, higher doses of the anticoagulant may be needed. It is

recommended that coagulation tests are closely monitored when anticoagulants are concurrently administered with azathioprine.

Cytostatic/myelosuppressive agents

Azathioprine should be used with caution in patients receiving, or who have recently received, other bone marrow suppressive agents.

Where possible, concomitant administration of cytostatic drugs, or drugs which may have a myelosuppressive effect, such as penicillamine, should be avoided. There are conflicting clinical reports of interactions, resulting in serious haematological abnormalities, between azathioprine and co-trimoxazole (trimethoprim/sulfamethoxazole).

There have been case reports suggesting that haematological abnormalities may develop due to the concomitant administration of azathioprine and ACE inhibitors.

It has been suggested that cimetidine and indomethacin may have myelosuppressive effects which may be enhanced by concomitant administration of azathioprine.

Aminosalicylates

As there is *in vitro* and *in vivo* evidence that aminosalicylate derivatives (e.g. olsalazine, mesalazine or sulfasalazine) inhibit the TPMT enzyme, they should be administered with caution in patients receiving concurrent azathioprine therapy (see **section 4.4 Special warnings and precautions for use**).

Methotrexate

When azathioprine is administered concomitantly with high dose methotrexate, the dose should be adjusted to maintain a suitable white blood cell count.

Vaccines

The immunosuppressive activity of azathioprine could result in an atypical and potentially deleterious response to live vaccines and so the administration of live vaccines to patients receiving azathioprine therapy is contraindicated on theoretical grounds.

A diminished response to killed vaccines is likely and such a response to hepatitis B vaccine has been observed among patients treated with a combination of azathioprine and corticosteroids.

A small clinical study has indicated that standard therapeutic doses of azathioprine do not deleteriously affect the response to polyvalent pneumococcal vaccine, as assessed on the basis of mean anti-capsular specific antibody concentration.

Ribavirin

Ribavirin inhibits the enzyme, inosine monophosphate dehydrogenase (IMPDH), leading to a lower production of the active 6-thioguanine nucleotides. Severe myelosuppression has been reported following concomitant administration of azathioprine and ribavirin; therefore co-administration is not advised.

Infliximab

An interaction has been observed between azathioprine and infliximab. Patients receiving ongoing azathioprine experienced increase in 6-TGN (6-thioguanine nucleotide, an active metabolite of azathioprine) levels and a decrease in the mean leukocyte count following infliximab infusion.

Miscellaneous

Furosemide (frusemide) has been shown to impair the metabolism of azathioprine by human hepatic tissue *in vitro*. The clinical significance is unknown.

Drugs known to induce (phenytoin, phenobarbital, rifampicin) or inhibit (ketoconazole, erythromycin) hepatic microsomal enzymes may alter the clearance of azathioprine.

Coadministration of azathioprine and captopril may result in increased susceptibility to leucopenia.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

Relief of chronic progressive renal failure by renal transplantation involving the use of azathioprine has been accompanied by increased fertility in both male and female transplant recipients.

Use in pregnancy

Category D

The decision to maintain or discontinue azathioprine during pregnancy, or to terminate the pregnancy, depends on the condition under treatment in which the maternal wellbeing has to be weighed against possible risks to the foetus. As a general rule, azathioprine therapy should not be initiated in patients known to be pregnant.

As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving azathioprine.

There have been reports of premature birth and low birth weight following maternal exposure to azathioprine, particularly in combination with corticosteroids. There have also been reports of spontaneous abortion following either maternal or paternal exposure.

Azathioprine and/or its metabolites have been found in low concentrations in foetal blood and amniotic fluid.

The rare possibility of neonatal leucopenia and/or thrombocytopenia which may not be clinically evident appears to be preventable by reducing maternal dosage of azathioprine if, at 32 weeks' gestation, the maternal leucocyte count is at or below $8.6 \times 10^9/L$. The possibility of neonatal immunosuppression is a serious and potentially fatal complication.

Extra care in haematological monitoring is advised during pregnancy.

Teratogenicity

Studies in pregnant rats, mice and rabbits using azathioprine in dosages from 5 to 15 mg/kg body weight/day over the period of organogenesis have shown varying degrees of foetal abnormalities. Teratogenicity was evident in rabbits at 10 mg/kg body weight/day.

Epidemiological evidence in humans indicates that the frequency of occurrence of congenital abnormalities in the offspring of maternal transplant recipients is similar to that in the general population.

As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving azathioprine.

Use in lactation

6-Mercaptopurine has been identified in the colostrum and breast-milk of women receiving azathioprine treatment. Breastfeeding mothers should be advised to consult their doctor, since use by breastfeeding mothers is not recommended because of possible adverse effects on the infant.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

There are no data on the effect of azathioprine on driving performance or the ability to operate machinery. A detrimental effect on these activities cannot be predicated from the pharmacology of the drug.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Hypersensitivity reactions

Several different clinical syndromes, which appear to be of an idiosyncratic hypersensitivity nature, have been described occasionally. They include general malaise, headache, dizziness, nausea, vomiting, diarrhoea, fever, rigors, exanthema, rash, vasculitis, myalgia, muscular pains, arthralgia, disturbed hepatic function, cholestatic jaundice, pancreatitis, cardiac dysrhythmia, renal dysfunction and hypotension. In many cases, rechallenge has confirmed an association with azathioprine.

Additional adverse reactions of low frequency have been reported. These include skin rashes (approximately 2%), steatorrhoea and negative nitrogen balance, Stevens-Johnson syndrome and toxic epidermal necrolysis (all less than 1%). It has been suggested that the imidazole side chain gives rise to hypersensitivity, whereas the 6-mercaptopurine (6-MP) molecule gives rise to cholestasis.

Immediate withdrawal of azathioprine and supportive circulatory measures have led to recovery in the majority of cases. Other marked underlying pathology has contributed to the very rare deaths reported.

Azathioprine should be **permanently** withdrawn after any such clinical syndrome.

Neoplasms benign, malignant and unspecified (including cysts and polyps)

Rare: neoplasms including lymphoproliferative disorders skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer *in situ* (see **section 4.4 Special warnings and precautions for use**).

The risk of developing lymphomas and other malignancies, notably skin cancers, is increased in patients receiving immunosuppressive drugs, particularly in transplant recipients receiving aggressive treatment, therefore such therapy should be maintained at the lowest effective levels. The increased risk of developing lymphomas in immunosuppressed rheumatoid arthritis patients compared with the general population appears to be related at least in part to the disease itself.

There have been rare reports of acute myeloid leukaemia and myelodysplasia (some in association with chromosomal abnormalities).

Haematopoiesis

Azathioprine may be associated with a dose-related, generally reversible, depression of bone marrow function, most frequently expressed as leucopenia, but also sometimes as anaemia and thrombocytopenia and rarely as agranulocytosis, pancytopenia and aplastic anaemia. These occur particularly in patients predisposed to myelotoxicity, such as those with TPMT deficiency and renal or hepatic insufficiency and in patients failing to reduce the dose of azathioprine when receiving concurrent allopurinol therapy.

Therapeutic use of azathioprine is associated with reversible, dose related increases in mean corpuscular volume and red cell haemoglobin content. Megaloblastic bone marrow changes have been observed, but severe megaloblastic anaemia and erythroid hypoplasia are rare.

Therapeutic use of azathioprine is associated with a reversible, dose related reduction in numbers of circulating total white cells, granulocytes and lymphocytes.

Azathioprine may produce thrombocytopenia which is dose related and may be delayed.

Alopecia

Hair loss has been described in 50% of renal transplant recipients receiving azathioprine and corticosteroids, but does not appear to be a major problem when azathioprine is used for other indications. It is reversible in over 80% of cases despite continuing immunosuppression.

Susceptibility to infection

Patients receiving azathioprine alone or in combination with other immunosuppressants, particularly corticosteroids have shown increased susceptibility to viral, fungal and bacterial infections, including severe or atypical infection and reactivation with varicella, herpes zoster, hepatitis B, Cytomegalovirus (CMV) and other infectious agents (see **section 4.4 Special warnings and precautions for use**). Viral, fungal and bacterial infections are very common in transplant patients receiving azathioprine in combination with other immunosuppressants.

Very rare cases of JC virus-associated PML have been reported following the use of azathioprine in combination with other immunosuppressants (see **section 4.4 Special warnings and precautions for use**).

Gastrointestinal reactions

Nausea, vomiting and gastrointestinal discomfort may occur during the first few months of azathioprine therapy. These effects are usually reduced by dosage adjustment and by administering the tablets in divided doses and/or after meals.

Serious complications, including colitis, diverticulitis, and bowel perforation, have been described in transplant recipients and appear to relate to high dosage of corticosteroids rather than to azathioprine *per se*.

Severe diarrhoea, recurring on rechallenge, has been reported in patients treated with azathioprine for inflammatory bowel disease. The possibility that exacerbation of symptoms might be drug related should be borne in mind when treating such patients.

Pancreatitis has been reported in a small percentage of patients on azathioprine therapy, particularly in renal transplant patients and those diagnosed as having inflammatory bowel disease. There are difficulties in relating the pancreatitis to the administration of one particular drug, although rechallenge has confirmed an association with azathioprine on occasions.

Pulmonary reactions

Reversible pneumonitis has been described very rarely.

Hepatotoxicity

Cholestasis and deterioration of liver function have occasionally been reported in association with azathioprine therapy and are usually reversible on withdrawal of therapy. This may be associated with symptoms of a hypersensitivity reaction (see **section 4.8 Adverse effects (Undesirable effects) - Hypersensitivity reactions**).

Hepatotoxicity may manifest by elevation of serum alkaline phosphatase, bilirubin and/or serum transaminases and is generally reversible after interruption of azathioprine. Periodic measurement of serum transaminases, alkaline phosphatase and bilirubin is indicated for early detection of hepatotoxicity. Hepatotoxicity has been uncommon (less than 1%) in patients with rheumatoid arthritis.

Rare, but life threatening hepatic damage associated with chronic administration of azathioprine has been described, primarily in transplant patients. Histological findings include sinusoidal dilation, peliosis hepatis, veno-occlusive disease and nodular regenerative hyperplasia. In some cases withdrawal of azathioprine has resulted in either a temporary or permanent improvement in liver histology and symptoms.

Azathioprine should be **permanently** withdrawn in patients with hepatic veno-occlusive disease.

Other

Other adverse reactions include sores in the mouth and on the lips, meningitis, formication, acute febrile neutrophilic dermatosis (Sweet's Syndrome), exacerbation of myasthenia gravis and dermatomyositis and alterations in the senses of smell or taste.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

Signs

Unexplained infection, ulceration of the throat, bruising and bleeding are the main signs of overdose with azathioprine and result from bone marrow depression which may be maximal after 9 to 14 days. These signs are more likely to be manifest following chronic overdose, rather than after a single acute overdose. Occasional reports describe ingestion of azathioprine from 0.5 to 7.5 g on a single occasion with apparent uneventful recovery

Treatment

Treatment is symptomatic and has included gastric lavage. If overdose occurs the blood picture and hepatic function in particular should be monitored. Azathioprine is partially dialysable but the procedure is of doubtful value since azathioprine is rapidly metabolised with entry of metabolites into tissue cells.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5. PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Azathioprine is an immuno-suppressive antimetabolite.

Azathioprine is an imidazole derivative of 6-mercaptopurine (6-MP). It is rapidly broken down *in vivo* into 6-MP and a methylnitroimidazole moiety. The 6-MP readily crosses cell membranes and is converted intracellularly into a number of purine thioanalogues, which include the main active nucleotide, thioinosinic acid. The rate of conversion varies from one person to another. Nucleotides do not traverse cell membranes and therefore do not circulate in body fluids. Irrespective of whether it is given directly or is derived *in vivo* from azathioprine, 6-MP is eliminated mainly as the inactive oxidised metabolite thiouric acid. This oxidation is brought about by xanthine oxidase, an enzyme which is inhibited by allopurinol. The activity of the methylnitroimidazole moiety has not been defined clearly. However, in several systems it appears to modify the activity of azathioprine as compared with that of 6-MP. Determinations of plasma concentrations of azathioprine or 6-MP have no prognostic value as regards effectiveness or toxicity of these compounds.

While the precise modes of action remain to be elucidated, some suggested mechanisms include: the release of 6-MP which acts as a purine antimetabolite; the possible blockade of -SH groups by alkylation; the inhibition of many pathways in nucleic acid biosynthesis, hence preventing proliferation of cells

involved in determination and amplification of immune response; damage to deoxyribonucleic acid (DNA) through incorporation of purine thioanalogues.

Because of these mechanisms, the therapeutic effect of azathioprine may be evident only after several weeks or months of treatment.

Clinical trials

No data available.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Azathioprine is well absorbed from the upper gastrointestinal tract after oral administration. Peak plasma levels occur to 1-2 hours.

Distribution

Both azathioprine and mercaptopurine are about 30% bound to plasma proteins.

Studies in mice with ³⁵S-azathioprine showed no unusually large concentration in any particular tissue, but there was very little ³⁵S found in the brain.

Metabolism

After oral administration it disappears rapidly from the circulation and is extensively metabolised to mercaptopurine. About 10% of the dose of azathioprine is split between the sulphur and purine ring to give 1-methyl-4-nitro-5-thioimidazole.

Excretion

The elimination half-life of azathioprine and of the active metabolite, 6-mercaptopurine is approximately 2 hours following single doses. Small amounts of the unchanged azathioprine and mercaptopurine are eliminated in the urine.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

No data available. See also **section 4.4 Special warnings and precautions for use - Mutagenicity**.

Carcinogenicity

No data available. See also **section 4.4 Special warnings and precautions for use - Carcinogenicity**.

6. PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

NOUMED AZATHIOPRINE film-coated tablets contain the following inactive ingredients: lactose monohydrate, maize starch, povidone, colloidal anhydrous silica, magnesium stearate, hypromellose, microcrystalline cellulose, PEG-8 stearate, purified talc, titanium dioxide.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C. Protect from light.

Safe handling of azathioprine tablets

Azathioprine tablets should not be divided, crushed or broken. Provided that the film coating is intact, there is no risk in handling film coated tablets.

6.5 NATURE AND CONTENTS OF CONTAINER


NOUMED AZATHIOPRINE 25 mg and 50 mg tablets are available in PVC/PVDC/Al or PP/Al blister packs of 100 tablets.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure:



Empirical formula: C₉H₇N₇O₂S

Chemical Name: 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine

CAS Number: 446-86-6

Molecular Weight: 277.3

Azathioprine is a pale-yellow powder, practically insoluble in water and in alcohol. It is soluble in dilute solutions of alkali hydroxides and sparingly soluble in dilute mineral acids.

7. MEDICINE SCHEDULE (POISON STANDARD)

S4 – Prescription Only Medicine

8. SPONSOR

Avallon Pharmaceuticals Pty Ltd
 Level 5, 7 Eden Park Drive
 Macquarie Park NSW 2113
 Australia
 Telephone No: 1800 930 999

9. DATE OF FIRST APPROVAL

26 February 2018

10. DATE OF REVISION

31 March 2021

Summary table of changes

Section changed	Summary of new information
All	PI reformat
4.4	Updated information on TPMT testing; Added information on NUDT15 testing; Added precautions on hypersensitivity; minor editorial changes
4.5	Updated information on interaction with xanthine oxidase inhibitors; added information on interaction with infliximab; minor editorial changes.
4.8	Added potential adverse effects (Sweet's Syndrome); minor editorial changes.
4.9	Delete use of activated charcoal as treatment option for overdose.
6.7	Minor editorial change.
8	Updated sponsor information.